CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology™s earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) - - Primary...
CG Oncology Announces Closing of Initial Public Offering to Purchase Shares
In a move that will be seized on as a sign that the IPO window is reopening in 2023, CG Oncology has not only become the first biotech to go public this year but overshot its own estimates.
CG Oncology Announces Pricing of Upsized Initial Public Offering
NEW YORK — Bladder cancer drugmaker CG Oncology will debut on Nasdaq Thursday morning in what is expected to be the first of at least half a dozen biotech IPOs before the spring.
CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year.
Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public.